Author

C.-L. Chiang

Observed names: C-J. Chiang, C-L. Chiang

Institutions: National Taiwan University, Taipei Veterans General Hospital

Observed institutions: National Taiwan University, Taipei Veterans General Hospital

OpenAlex ID: A5060021655

980MO Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small-cell lung cancer (ES-SCLC): IMforte Asia subgroup results

2025 · Y. Yang, K.H. Lee, et al. · Annals of Oncology

P1.07.08 Comparing Outcomes of Different Surgical Methods for Small-Sized NSCLC With VPI- A Population-Based Study

2025 · X-H. Chiang, C-J. Chen, et al. · Journal of Thoracic Oncology

EP08.02-027 T790M Detection Rate After First-Line Treatment with Bevacizumab Plus 1st or 2nd Generation EGFR-TKI in Advanced NSCLC

2022 · C.-H. Kuo, P.-L. Su, et al. · Journal of Thoracic Oncology

EP05.01-003 First Real-World Data on Unresectable Stage III NSCLC Patients Treated with Durvalumab after Chemoradiotherapy in Asia Area

2022 · C. Kuo, T.-Y. Yang, et al. · Journal of Thoracic Oncology

Works count: 4

Citation count:

H-index:

I10-index: